Can-Fite Biopharma Target Price

Can-Fite Biopharma's target price stands at $6.5. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $6.5 for CANF implies 86.2% upside versus today's price ($3.49). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Can-Fite Biopharma's target price evolved across reporting periods, while the comparison chart places CANF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Can-Fite Biopharma's reading of $6.5 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.